



(51) International Patent Classification:

A61K 47/68 (2017.01) A61K 47/62 (2017.01)
A61K 47/61 (2017.01) A61P 35/00 (2006.01)
A61K 47/60 (2017.01) C07K 16/28 (2006.01)

(21) International Application Number:

PCT/EP2024/084933

(22) International Filing Date:

05 December 2024 (05.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23214775.1 06 December 2023 (06.12.2023) EP

(71) Applicant: **HEIDELBERG PHARMA RESEARCH GMBH** [DE/DE]; Gregor-Mendel-Str. 22, 68526 Ladenburg (DE).

(72) Inventors: **MÜLLER, Christoph**; c/o Heidelberg Pharma Research GmbH, Gregor-Mendel-Str. 22, 68526 Ladenburg (DE). **GRUSS, Hendrik**; c/o Heidelberg Pharma Research GmbH, Gregor-Mendel-Str. 22, 68526 Ladenburg (DE). **HECHLER, Torsten**; c/o Heidelberg Pharma Research GmbH, Gregor-Mendel-Str. 22, 68526 Ladenburg (DE). **PÁLFI, Anikó**; c/o Heidelberg Pharma Research GmbH, Gregor-Mendel-Str. 22, 68526 Ladenburg (DE). **SCHMITT, Marisa**; c/o Heidelberg Pharma Research GmbH, Gregor-Mendel-Str. 22, 68526 Ladenburg (DE).

search GmbH, Gregor-Mendel-Str. 22, 68526 Ladenburg (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(54) Title: ANTIBODY-DRUG CONJUGATE COMPRISING AN ANTI-GUCY2C ANTIBODY AS WELL AS METHODS OF PRODUCTION AND USES THEREOF




Figure 5

(57) Abstract: The present disclosure relates to new antibody-drug-conjugates (ADCs) comprising a favorable modular linker linking the pharmaceutically active drug substance with the antibody. The present disclosure further relates to methods of producing the antibody-drug conjugate as well as to uses thereof and pharmaceutical compositions comprising the same. Embodiments of the present disclosure have been particularly developed as antibody-drug conjugates for use in the treatment of Guanylate Cyclase 2C (GUCY2C)-positive gastrointestinal cancers and will be described hereinafter with reference to this application. However, it will be appreciated that the present disclosure is not limited to this particular field of use.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*